Dr. Charles Mok discusses minocycline research for MS that was active through 2010, particularly in Canada, and alleges a pharmaceutical company acquired that research to redirect trials toward a proprietary drug costing $60-70k per year. He argues for investigating lower-cost alternatives that may work as well or better.
Chapters
So until about 2010, there was a lot of research on minocycline for multiple sclerosis, particularly in Canada, where they pretty much have self insured, one insurance policy they'd have an interest to reduce drug costs. And a big pharma company came in and basically bought out the research and got them researching their drug, showing that their drug worked just as good as minocycline. So let's, let's research our drug, which costs 60, $70,000 a year. So this talk is not about bashing pharmaceutical companies that do a lot of good work, but they're very expensive and potentially we can't afford these increasing cost of drugs in the country. So should we look for practical alternatives? Work just as good, in some cases better.